NCT06638931 2026-04-15ANTARESInstituto do Cancer do Estado de São PauloPhase 2 Recruiting28 enrolled
NCT03093116 2026-04-03TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 5 FDA